Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Oct 18;51(1):1065.
doi: 10.1007/s11033-024-09997-2.

Erythropoietin and glial cells in central and peripheral nervous systems

Sara Haratizadeh  1 , Mozhdeh Nemati  2 , Mohsen Basiri  3 , Masoumeh Nozari  4   5
Affiliations
Review

Erythropoietin and glial cells in central and peripheral nervous systems

Sara Haratizadeh et al. Mol Biol Rep. .

Abstract

Erythropoietin (EPO) is the main hematopoietic growth factor prescribed to overcome anemia. It is also a neuroprotective agent. EPO binds to the erythropoietin receptor (EPOR), expressed on neurons and glial cells in the central nervous system (CNS), and exerts its neuroprotective potencies through the EPO-EPOR complex. The mechanism of the signal transduction pathways of EPO on glial cells is defined. EPO-EPOR complex can affect neurological disorders, such as Alzheimer's disease, Parkinson's disease, ischemia, retinal injury, stroke, hypoxia, trauma, and demyelinating diseases, through acting downstream signaling pathways. This review focuses on the roles of EPO in different types of glial cells (astrocytes, microglia, oligodendrocytes, and Schwann cells) and their relationships with signaling pathways. Information on the non-erythropoietic action of EPO and related signaling systems in connection with glial cells could enhance EPO treatment to restore different CNS disorders and propose new perspectives on the neuroprotective potential of EPO.

Keywords: Erythropoietin; Glia cells; Neurodegenerative disease.

PubMed Disclaimer

References

    1. Murakami M, Kiuchi T, Nishihara M, Tezuka K, Okamoto R, Izumi M et al (2016) Chemical synthesis of erythropoietin glycoforms for insights into the relationship between glycosylation pattern and bioactivity. Sci Adv; 2(1)
    1. Pathipati P, Ferriero DM (2017) The Differential effects of Erythropoietin exposure to oxidative stress on microglia and astrocytes in vitro. Dev Neurosci 39(1–4):310–322 - DOI
    1. Liu M, Wang AJ, Chen Y, Zhao G, Jiang Z, Wang X et al (2020) Efficacy and safety of erythropoietin for traumatic brain injury. BMC Neurol 20(1):399 - DOI
    1. Haratizadeh S, Ranjbar M, Basiri M, Nozari M (2023) Astrocyte responses to postnatal erythropoietin and nano-erythropoietin treatments in a valproic acid-induced animal model of autism. 130(March):1–8
    1. Haratizadeh S, Ranjbar M, Basiri M, Nozari M (2022) The effects of postnatal erythropoietin and nano-erythropoietin on behavioral alterations by mediating K-Cl co-transporter 2 in the valproic acid-induced rat model of autism. 2023; (September :1–10

MeSH terms

LinkOut - more resources